TrendyNews

 As the COVID-19 pandemic gradually recedes, manufacturers of mRNA vaccines find themselves grappling with surplus vaccine doses and dormant production facilities. Traditional vaccines typically contain weakened or inactivated forms of pathogens, such as bacteria or viruses, to trigger an immune response. However, a groundbreaking advancement in vaccine technology has led to the development of mRNA vaccines. Unlike conventional vaccines, mRNA vaccines utilize a molecule known as messenger RNA (mRNA), which plays a crucial role in protein production within cells. mRNA vaccines work by delivering a small segment of genetic material, mRNA, into the body. This mRNA contains instructions for cells to produce specific proteins, mimicking components of the targeted pathogen. Once inside the cells, the mRNA prompts protein synthesis, triggering an immune response. This innovative approach allows the immune system to recognize and mount a defense against the pathogen without exposure to the act

The 2024 Global Hepatitis Report from the World Health Organization reveals staggering figures: in 2022, 254 million individuals grappled with Hepatitis B, while another 50 million battled Hepatitis C. In 2022, India ranked second globally in Hepatitis B and C cases, following China, with a total of 35 million infections. Hepatitis, an inflammatory condition affecting the liver, is primarily caused by the hepatitis virus. This virus is classified into five distinct strains: A, B, C, D, and E. While hepatitis A and E typically result in acute and self-limiting infections, hepatitis B and C are known to progress to chronic states, posing significant risks such as liver cirrhosis, liver cancer, and hepatitis-related mortality. Read More About- Hepatitis Infection